Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report

The reason that immune checkpoint inhibitors have not been widely applied to pancreatic cancer treatment is probably because of low immunogenicity or dense stromal fibrosis. Recently, only pembrolizumab was recommended for DNA mismatch repair deficiency or high microsatellite instability by National...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fan, Li, Xiaomin, Liu, Haisheng, Liu, Rongfeng, Zhou, Zhiguo, Zhang, Yi, Chen, Jingli, Tian, Ye, Pan, Chaohu, Meng, Qingju, Liu, Yibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481288/
https://www.ncbi.nlm.nih.gov/pubmed/35946538
http://dx.doi.org/10.1097/CAD.0000000000001334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481288/
https://www.ncbi.nlm.nih.gov/pubmed/35946538
http://dx.doi.org/10.1097/CAD.0000000000001334

Ejemplares similares